merck to focus on innovation.es innovation look like at merck? >> well, for merck, coming forward with transformational medicine. a recent example is our new investigational medicine for cancer. it's one of the first in a series of what are called immunotherapies for cancer. it defeats the body defeat the tumors. that's the kind of thing a company like merck exists to do. >> how do you decide which drugs are going to be in the pipeline for long-term development? >> first of all, those decisions are made by our very capable research scientists. they're not made in the first instance by made. and that's a good thing for people, that they're investors as well as patients being made by those very able people. but generally speaking, where america tries to go with its research dollars, we look for the intersection of unmet medical need and scientific opportunity. so we want to be in those areas like cancer, like alzheimer's, like hiv, where there's great unmet medical need around the world, a need for better therapy, a

merck ceo ken frazier and a first on cnbc interview. it away. >> joining us is the ceo of merck, ken frazier. thank you for joining us. >> thanks for having me. >> we've seen really big deal news. you guys did two really interesting deals in 2014. you bought a company for hepatitis c and a company for antibiotics. tell us about that strategy not doing the big ones doing the specialized areas. are you going to do more of that in 2015? >> absolutely. both of those deals are important because they're in areas that we want to focus on because we believe we have the opportunity to lead in hepatitis c and also in anti-microbial resistance. merck has had a long history in infectious diseases. we intend to come forward with important medicines. >> let's talk about the cubist deal. the last time we spoke you had just done it. hours late they're surprising news about the patent for the biggest drug in that deal. tell us whether that changes the strategy with that deal. >> it doesn't change it at all. it was one of the many scenarios we thought ab

that merck number -- >> that's where i wanted to go. pfizer and merck, you own both still? >> yes. it's all about growth. it's not about defense. everybody loves to call these defensive. they're not. it's about growth. you look at merck and you look at the hepc area and lung cancer where they're showing much more in the pipeline that could come to the market soon. it's why these stocks are going higher. >> you fade the cisco high? of all the names that you mentioned, that's the one i'm most suspicious. >> that's what i thought. >> but why? >> it's not an all-time high. >> until you look at cisco, you look at big cap, you look at some of the -- >> all right. so it's -- >> the bubble days, i mean, this thing has had much, much higher valuation in price. >> all right. coming up, if you want to get your hands on an iphone, this is not the way to do it. it's our worst trade and it's coming up. [container door opening] ♪ what makes it an suv is what you can get into it. ♪ [container door closing] what makes it an nx is what you can get out of it. ♪ introducing the first-ever lexus nx tur

. >> second best stock of the year is merck. >> good interview yesterday with merck.going -- i'll blow it wide open. my sblaefbelief is not that any of the drugs that we currently talk about, lung cancer drug, i think merck is working on alzheimer's and plaque reduction. >> if there were a real therapy to combat alzheimer's, it would immediately become the largest drug in world history. >> how about a pill that you would take. that's holy grail. a pill that you would take that makes it that you don't have plaque in your brain. >> in other words like lipitor for alzheimer's. >> bingo. and merck had it first and then warner lambert came out with a better version. but merck, 1985 '86, nevacor. and then they took to another level. >> until gilyard until now. >> hepatitis c, yes. >> in a tape like this, even downgraded names like hp doing pretty well. >> what happened with the volatility in this market? holy cow. oil up for about 30 seconds. not bad. >> that's all it takes. >> so with that dow up 230 as jim says. every component is in the green. led by unh. bob pa is anisa

when you look at boeing and merck they led the dow.with that, one of the reasons we talked about was the demand for their aircrafts. they recently came out with numbers, saw higher demand. merck and boeing are the winners. the two losers in the dow 30 are jpmorgan and caterpillar. jpmorgan when they came out, many of the banks came out with numbers, and jpmorgan led the way on this one, the legal fees. and that was problematic. that stock is down 12%. and caterpillar, they came out, numbers were atrocious and the forecast going forward, you mentioned commodities, liz, they thought about oil and how it's going affect the 2015 numbers. the theme is the strong u.s. dollar. liz: that is the big theme, got to watch. some companies are very adept at maneuvering through a strong dollar and hedging. others have no idea what to do. it shows in earnings. this season has not been kind to big banks. financial heavyweights from goldman sachs to bank of america disappointed investors in the fourth quarter. many are lagging. is it time -- forget shak

merck says -- merck has something, too. these companies are on the verge of -- they're doing this personalized medicine. the results are getting better and better and better. we're seeing it in many different companies. you know agio the stock goes up plenty. i'm talking to a lot of companies this week because what they're doing is making it so that they're not using chemo therapy. and chemo therapy is going to look like bloodletting in the end. they had put themselves up for sale. there was, it seems, a process. that has been confirmed. not expecting anybody to come in over the top there. they do have a date when they're going to hear from the fda on a drug. but that is -- even if they get turned down on this nat par, i believe at least -- >> delayed in october! and goldman downgraded. that was wrong. >> but it doesn't appear to be a merck situation. >> no not at all. by the way, brent saunders is on today. the activist. >> nice. >> and again, the stock will go up again. i'm just telling you. that guy is fabulous tv. told

outdone by merck.ed, some reporting, people may miss it, you think may have to do with alzheimer's treatment merck may one day have coming. i will say stocks have been strong to start the year whether biotech or pharma with bristol-myers up 7%. >> bristol-myers rerated a couple of drugs nobody's caulking about. mercking i believe have alzheimer's, they're not talking about it. >> with jpmorgan health care conference concluding today. >> we did some work. after the conference stocks don't automatically go down. this time they had a big run. i had the arms dealer of the guys buy -- people feel the cube is deal bought a day too soon, the deal will work for merck. look at this thing, i mean this is the company that has -- makes cancer cells commit suicide -- good article in "the new yorker" i had every single day one or two, i got three biotechs today, they are doing things right now in immunotherapy changing death sentences. i'm going to say it changing death sentences. urgency of the fda saying listen, f

merck and coca-cola. interestingly enough. let's go to the exchange and spend sometime with these folks. as we begin the new new year cathy jones with us here today and ron wiener. kenny pulcari. eric restabin and mr. market himself rick santelli in chicago. what do you make of this rollover we see today as we mentioned? we mentioned really began in earnest this morning in europe. >> what's going on is extremely significant with regard to what's going to make a change. next month, next quarter, three quarters from now. i think the news out of europe isn't going to change dramatically in a positive fashion any time soon. and mario draghi's going to be front and center stage. with respect to energy hey, investors paid for technology that resulted in much lower prices for everybody. and if they go bust the technology's still there and a company after them will buy it cheaper and a company after that buys it cheaper. i think it's the gift that keeps on giving. investors, thank you for investing. but sayonara. middle class shouldn'

lori: one stock to the downside, merck. >> ebola tries good news.elopment from a skin cancer drug. that is also good news. the stock is up 1 1/2%. and bernstein raised them to outperform with a $68 target. that is $10 higher than where it currently is at the moment. on a day we're down 327 points. we're about 30 points off the lows of the day but certainlies that been selling across the board. oil in europe seems to be the culprit. [closing bell ringing]. lori: the bells ring on wall street. adam: the dow closing down 324 points. hasn't settled yet. s&p down 37 points. nasdaq down 73 points. russell 2000 also down today. "after the bell" starts right now. lori: i about the way, quick mention, coca-cola was slightly hower as far as dow components go. much lower market a are you session. let's get into it with our market experts. joe keating, center stage bank. he says there is good opportunity to plate energy sector right now. brian pierce from hennessey fund will tell us how to profit from increased consumer spending a joining us phil fl

the other is licensed by merck. the house passed a bill approving construction of the keystone xl pipeline. all members except one republican along with 28 democrats voted for the bill. the white house issued a veto threat this week. it says its position in posture remain unchanged. this comes after the nebraska supreme court threw out a lawsuit challenging the pipeline's proposed route through the state. still ahead -- maryland governor martin o'malley is opening up about what he will do after he leaves office. when he plans to announce whether he will run for president next year. and get ready for much colder weather. >> coming up and sports, a new face in ashburn. there's a place online where you always get more than you pay for tjmaxx.com. better brands at better prices to help you maxx what matters most to you... anytime. maxx life. shop tjmaxx.com. >> president obama announced a plan for to years of community college for anybody who wants it. he talked about the idea during a visit to tennessee. caroline tucke

the real winner was merck.er some positive comments from bernstein and ebola vaccine trials they're working on and lung cancer drugs also in the works. so that's why merck was a winner. back to you. charles: up 55 cents and the big winner today. all right, guys, here to help us out, the investment pros. jim frischling's with us, hillary kramer's back as well. monster worldwide senior vp joni courtney, hitha herzog, our retail expert looking great with the, what's that thing called, the the necklace thing? >> mood necklace. charles: all right, and matt mccall. let's dig into the first real, real deal. we were under pressure at the very beginning, and here's the thing, initially stocks took their cue from news out of europe. the euro hat a nine-year low, but then it felt like oil became the big story when it broke particularly under $50 a barrel. in some ways today's weakness was sort of telegraphed. we had these the big rallies, and they fizzled day after day. the street wrote it off, holiday trading, light volu

. >> chicago merck. >> thanks for joining us. power begins now. >>> "halftime" is over. "power lunch" and the second half of the trading day start right now. >>> we've got power. we've got lunch, but what we don't have here in engelwood cliffs is much snow. at least not yet. but they do have it over there in pennsylvania. that's video from the keystone state already getting hit. new york city, right now and that includes wall street of course, is under a blizzard warning. the farther out on long island you live the worse this blizzard may be. the impact of course goes far bewrond the northeast. we're talking mass airline cancellations and the stocks that do well when the weather goes bad. sue herrera has our top story. the snow. she's right here at hq. >> thank you, ty. right now we're going to go to morning city mayor bill deblasio holding a news conference and a presser. let's listen to what he has to say. >> we have very high winds. we know we'll have low visibility and lots of conditions that make travel unsafe. we will give you constant updates as we get information

''glaxo- smith kline'' y ''merck'' --- cientficos han logrado inscribir a casi 3 mil personas para que. quienes sern divididos en tres grupos... los dos primeros recibirn la vacuna y el tercero recibirn una sustancia terapetica...tom ar un aÑo conocer los resultados de este nuevo tratamiento.. lorena/ms --- segn un estudio ciertos analgsicos podran afectar a mujeres en edad frtil... take vo --- una investigacin federal encontr que un 39 por ciento de la mujeres en edad reproductiva que estn inscritas al programa medicaid y un 28 por ciento de registradas en planes privados de salud han solicitado en el pasado analgsicos narcticos...esa s pastillas que se toman cuando hay dolores intensos... --- los investigadores dicen que las mujeres que toman estos medicamentos y no saben que estn embarazadas pueden exponer a sus bebs a problemas del corazn... --- por eso gestantes y seÑoras que quieran tener un beb deben consultar con su mdico sobre el uso de estas pastillas... lorena - top vo --y tambin en materia de salud, investigadores revelan un informe en el que se indica que las voces de fami

which worried about the inflationary effects of such large purchases and german chancellor angela merck el before draghi even announced the plan cautioned european neighbors wouldn't let them off the hook for acting important structural economic reforms. despite telegraphing the move for us draghi managed to surprise markets. the euro fell to an 11 year low and italian ten year bond yields dropped 16 basis points to 1.6%. stocks soared around the world but there's skepticism. if draghi and ecb are out front, it's the first time since the financial crisis began. for "nightly business report," i'm steve liesman. >>> from athens greece davos switzerland, and london england, we begin in frankfurt, germany, with annette. >> reporter: they have announced the quantitateyate easing program, meant to spur inflation in negative territory and also to have the euro zone in its economic recovery. the volume was a little bit more and also but positive heard from the european central bank today is that there is a notion of open endedness in that program, so that means it could run longer than septembe

hit record levels and to merck contributed to rising valuations. what could burst biotech's bubble? front lighter points to two main issues. >> a looming potential price war, we saw some evidence of that. there will be some discussion of other drug classes at risk of that. the concern over the supreme court and obamacare. >> reporter: the j.p. morgan conference can be a big news maker with volatile health care stocks. companies release clinical trial data and announce deals at the summit. rec analyst michael yee said vertex are two important stocks to watch. >> there's a lot of wealth of data and smid caps as well but i think we come out of the conference with a bullish view and biostocks trading up on that. >> reporter: we'll let you know next week. for "nightly business report," i'm meg terrell. >> one of the most watched experimental drugs, and that is where we begin tonight's market focus. the therapy showed promise of being able to repair optic nerve damage and the hints that could help those suffering from multiple sclerosis. some results show it lacked clarity. the wholesale

the johnson and johnsons the mercks. we also had a substantial position in i.t. and for technology with intel being a big holding of ours. the stock that two or three years ago people thought couldn't bang its way out of a wet paper bag, it really came through with a rise of over 40%. >> randall thank you so much for spending time with us. we appreciate it. have a great weekend. >> thank you for having me. >> randall elie with the edgar lomaxwemax company. >>> another upstart looks to give a woman's touch. >>> nearly two months after the violence and looting that ripped apart ferguson missouri some of the city's small business owners are still trying to rebuild and recover. and they're getting help from some unexpected sources. kate rogers has more from ferguson. >> i was shocked. i went into shock. >> i felt totally violated. >> scary. you don't know where to go. >> reporter: wau knee that morris been in business for nearly 30 years watched the location she had in town for a decade burned to the ground on the news. >> i feel a lot of people hurt by this. >> repo

the drug makers including regenerators and merck and ai lum nah. announced the $200 million investment in precision medicine medicine. treatments for diseases created right here in the united states. >> because we shouldn't just celebrate innovation. we have to invest in innovation. >> reporter: so what is precision medicine? it's described as the right treatment for the right patient at the right time. therapy is more tailored to the underlying drivers of disease. the government will start with initiative on cancer driving understanding of its root causes to spur drug development. it will also build a national database of health information on at least a million volunteers. with everything from genetic data to health records to lifestyle habits. jor gee leads at regeneron. using research to drive drug development, a method that led to pcsk 9 inhibitors aimed at lowering cholesterol. >> if we define what makes us more susceptible to disease or keeps us protected against disease, we can use that. we can use that to come up with medicines that mimic

it gives another year or nine months to prepare to fight against competition from pfizer merck, and novartishen there are earnings, he will be here next to me. no doubt about that. we had to break. 48 minutes into the session here. the ftse 100 is up. the dax in germany is up 44 points. if you want to know what is happening, i will bring you the price. it is down for a third straight day. after the break, we're going to talk rbs disposing most of the toxic assets by the end of the year. it is a bloomberg scoop and a little bit of good news for rbs. we will talk about that. >> welcome back to on the move. breaking news. the royal bank of scotland is set to close the housing unit. we are joined by manus cranny. ahead of schedule. decent news. >> they set up the bank and took the most toxic assets that nobody wanted. they stuck it in there. they got rid of that and they are way ahead. there is a reason why he was the only executive at the level to really march out the door and go , i am a bonus. he is ahead of the task. he is one year ahead of schedule. 15% of stuff that god would not want to t

home depot, wal-mart and merck.vers two names, constellation brands and great numbers of beer went down. family dollar, the profits fell there, down 1/2% and chipotle talk about stocks, when will it happen? stock hitting of new high 3.5%, $7.27 in change. sheila! you see this ball control? you see this right? it's 80% confidence and 64% knee brace. that's more... shh... i know that's more than 100%. but that's what winners give. now bicycle kick your old 401(k) into an ira. i know, i know. listen, just get td ameritrade's rollover consultants on the horn. they'll guide you through the whole process. it's simple. even she could do it. whatever, janet. for all the confidence you need. td ameritrade. you got this. stuart: look at the stock price of yelp, the in allegations to manipulate reviews on its web site. in favor of advertisers. looking at the recommendations software since last year, close the investigation, stock is up 2%. is really cold out there. look at the current temperatures those are temperatures below

already merck has bought a company. that had already been one of shire's targets.side by the abbvie offer. it is back on the road, putting m&a front and center. the best form of defense is attack. they do not want to be hunted again and they are going to will up -- build up. >> are we going to see more m&a activity surrounding rare diseases? >> i think we are. shire are not the only company in this area. sanofi is another big player in rare diseases. they've been vocal about the fact that they are looking for more acquisitions in that area. there are thousands of rare diseases for which there is no treatment. there are small biotech companies developing treatments. as long as the fda incentives are in place and biotechs are developing treatments, we are going to see more. where you are not going to see so much m&a in pharma is in the tax inversion arena. with the changes that congress made at the end of last year to take some of the appeal of tax conversion away, i think we will see less of that and more deals that have a strategic rationale to them. >> all right.

you announced an agreement with bristol-myers and merck about cancer drugs.here are your venture capital guys on the deal side? you are they meeting with and talking to that they are most excited about? >> if you look where lilly ventures has placed investment half are in oncology. the other half are split between anti-infect this cardiovascular some devices. neuroscience is going to grow as we begin to understand better the factors around diseases like alzheimer's. >> i also wanted to ask you, you have a big animal health business p we've seen bill ackman and pershing activists get involved. they've been known for train to force deals. something the size of the zoetis, is that a kind of investment you might be interested in making? as we see some news potentially develop. >> we are not interested in zoetis, per se. we did complete our acquisition of animal health. we are interested in more deals in the animal health space. our animal health portfolio. it would be on a smaller scale. with the novartis acquisition we are number two or number three in animal he

merck -- i like those names.ike johnson & johnson, i just want to wait right now for any kind of a pull-back on j and j. >> the rest of the company is going to contract. this is the part where the stock move 2013 from 63 up to 90 bucks. that's where you really find the stock struggling to find the next level higher. >> you wait for them to report on the 20th. this is a company now that's pretty diversified. it's not just medical devices. you could spin these guys off into three companies and have three monster companies. >> still ahead on the program we'll tell you the one oil stock traders are betting will crash. yes, crash, this year. that's next. attention investor! vectorvest mobile is here and it's free! make faster, smarter, better trading decisions with vectorvest mobile. the most powerful app or managing your portfolio from the palm of your hand. only vectorvest mobile analyzes, ranks and graphs... ...over 16,000 stocks worldwide, everyday,... ...and gives you clear buy, sell, hold recommendations... ...o

you can see leading the dow, merck, verizon is up there.tors likely thinking the declines of the last couple session perhaps overdone. so health care leading the way. also utilities a strong sector in the s&p 500. investors looking for yield with interest rates now down once again. even though we're off the session lows, today, sell-off is not without conviction. why the volume currently running 24% above the average. will a high-volume flush out set the stage for a market rebound. teddy is down at the floor of the new york stock exchange. we're seeing some buying into the close. what's behind that? >> first of all, we're still down on the day, but clearly down 64 is not as bad as being down 200 especially when you add in down 300 and change yesterday. but the bottom line is, short of the market rallying to the plus side in the next couple of minutes, which is possible as we get to the end of the trading day. still two down days back-to-back. tough way to start the year. only a couple of days in the year. a couple of trading days won't make

right now merck has a fantastic product for immunooncology.came out from but it took somebody with a balance sheet of merck to be able to make the big bets. they're working on ten different cancers now. they're going to take the same platforms and try it on ten different cancers. that's where you need the big pharma. >> which institute? >> this is to m.i.t. -- this was a small shop right next to m.i.t. and part of a scientist whose name i don't know. but it was part of an asset sharing that merck got. >> so something that seems to be present over ten different types of cancers. that would be -- >> well, this platform works in melanoma. now they're going to validate that in lung cancer. so when you get something like this, you don't know where the limits are. and that's where you need the big bucks. and you have to be somebody with that kind of balance sheet to be able to do that. >> it's interesting. >> fred fortunately is going to be with us for the rest of the show. we have time to talk about the exciting prospects coming up. stay with us. >

. >> recently mercke bought cube s pharma. i see that shire is taking a leap here.a huge drug you talked to us natpara neither you nor nps seems to be worried about an approval. >> the drug is reviewed by the fda. we are confident that it will be approved in the u.s. >> i want to go over what it is like to be an investor in these companies. you have convinced people and i know many people watch the show. goldman sachs november 11 trends short. they didn't like it. october 24 they downgrade your stock because of uncertainty about natpara. how do we keep investors in stocks where the future is so great when we know it is a bumpy ride? >> it will be a bumpy ride and it is absolutely not a linear growth. remember, it is one patient at a time every patient counts. so some quarters you have many more patients. others you don't. and all of a sudden what you need to look at is a trend and not really at the point for point basis. >> shire is very confident that this deal is a creed -- >> this is what they said. what i can say is they have experience of rare disease. they hav

merck, verizon, those were some of the leaders. you mentioned oil. low was below $48 a barrel. some of those names. transocean. those come under pressure. certainly, no doubt. there were a few winners. the question is whether or not now today that we have this big sell-off with some heavy volume, what do they do tomorrow? the winner was twitter. some positive comments from some of the board members. boost to the stock. among others. back to you. charles: we'll talk oil. and we'll talk twitter as well. here to help, the investment pros. jim frischling. back with us. great to have you. oliver. did you change firms? >> well, we got bou bought out. >> brute man brothers. (?) joanie is with us. hitha, our retail expert. is retail holding up? we'll ask you about that. matt mccaul founder of penn financials group. obviously a lot to talk about. let's dig into the first real, real deal. you know, it's getting old. once again a solid start to the session fades quickly. morphs into a swift dramatic sell-off. the speed of these collapses has to be setting off alarms. still, i didn't sense

when you consider that mercke paid 3.8$3.8 billion you may be wondering. encouraging speculation. last year's eighth best is amicus. advanced enzyme therapy designed to treat rare conditions came up with a bunch of positive updates. number nine ptc therapeutics. company is currently launching first drug in europe. last but not least the tenth best performing for 2014 was esperion developing once daily pill for people with super high cholesterol. i see no reason to change given the number of people for whom statens don't work well. here is the bottom line. a couple escaped. i think the same factors that caused the group to war last year could continue to let it rally in 2015. so many of these bio techs have transcended the one drug wonder syndrome and are now developing technology platforms that could help them create many big drugs which is why i think it makes sense to buy the drugs with powerful platforms when they come in even as it is perhaps the most painful thing you can do in this newly treacherous market. much more mad ahead including my look at so

all dow components are lower with the exception of pfizer and merck. they have been the stars of 2015. jpmorgan and goldman sachs weighing on the dow. financials have been particularly weak. jpmorgan came out with numbers that missed and also oil. take a look what is going on with oil. moments ago, traders say what is going on with oil? it is rallying, up a buck 45 right now. you see the big spike right there. we're looking at that very closely but that has been weighing on markets overall. back to you. melissa: interesting nicole. thanks so much. oil is cheap but comes at a price with hundreds of thousands of jobs hanging in the balance we'll take a trip to one of the hardest hit states. >>> plus knowing the mayor isn't enough to get awe free meal in at least one restaurant in china. why good looks may be the only way to free eats. do you ever have too much money? ♪ in my world, wall isn't a street... return on investment isn't the only return i'm looking forward to. for some every dollar is earned with sweat, sacrifice, courage. which is why usaa is

you have a few names in, you know johnson & johnson merck pfizer, holding on to some gains, some technologiesfor the most part still a lot of weakness. some of this cops from economic news, durable goods for example. so we're seeing a slowing economy coupled with earnings which have been a miss and disappointment. caterpillar in particular. caterpillar comes out and basically says commodity prices are hitting their profits. going forward, the low oil prices will bring a soft 2015. looking at copper basically five 1/2 year lows. iron ore coal these are things which they're involved with. with that down 7 1/2% for caterpillar. so right now the dow is down almost 250 points. we had been down 370 and on the these of some weak economic news in particular and tough earnings we're really just seeing selling across the board today. back to you. melissa: nicole, thank you so much. much of the northeast still digging themselves out from a massive amount of snow. some parts of massachusetts got more than two feet. it is still coming down. poor molly line braving the elements in boston. how is it going t

let's get to jackie deangeles at the new york merck exchange. >> good afternoon, tyler. what's interesting as i'm standing here listening to your conversation, i'm watching the spread between brent and wti tighten right before my eyes. about 40 cents right now. $45.82 for brent crude, which is seeing more of a steep selloff than wti. $45.33 is where we're standing on the domestic contract, which did drop under $45 earlier this morning. a couple of things that we haven't reported today. the first adding to the pressure is the expectation of an inventory build tomorrow when we get the department of energy report. that will be probably bearish for prices if we do, in fact, get that build. of course, a stronger dollar is adding pressure today. even some news from the eia that they're bumping up their 2015 demand forecast. not really enough to get these markets higher. meantime, this spread is very interesting because the last time that we saw wti overtake brent wasn't until from july 2013. it happened very briefly. it happened more significantly in july of 2010, but everyone

and pointing a finger at merck, writing that growing tolerance of violence and warfare has also playedhe book is "a call to action >>> action ." i talked to him and asked him what inspired him? >> they have had programs of an active nature in 79 different countries, and since i left the white that's what we have been doing. and we have gotten to know people in all kinds of nations, particularly in third world countries where women and girls are abused. but the people who can do something about it, now have 23 recommendations in the book to help solve these problems, but particularly in the rich world like the united states. and a lot of the problems occur in the poorest countries, but are also present here in the united states. for instance slavery, the slavery scene is much greater than it was during the 19th century when black people were brought out of africa for slavery. there is about $32 billion worth of human trafficking every year. and the state department now is required to report on this annually, and they reported last year, that 800,000 people were sold across international

they are working with players like merck.last night drugs that strip cancer cells the ability to hide from your immune system like blood hounds and a platform where they are creating vaccines to produce an immune response against a given patient's cancer profile with an exciting compound that treats a type of brain cancer. have they reason up too much? this rally is just beginning. let's look with the founder and ceo of the company. welcome to "mad money." good to sue oweee you. congratulations on your success. just give us where you are with immuno therapy. >> the importance is the fact that we have a whole spectrum of tools in the check point field. you mention the the check point field inside because of their vision and capabilities allows us to get to the finish line quicker, better and more complete fashion. >> what happens? they read you know them or they read some of the articles about what you're doing and pick up the phone and call you? because i'm always fascinated by these deals. how does insight know what agenus i

merck, walmart, verizon, mcdonald's, chevron, at&t, caterpillar and other ones are down. >> that's a lot. time now to get -- >> 76%. >> consumer electronics show. jon fortt with the ceo of at&t mobile and business solutions. take it away. >> all right. thanks, mandy. ralph de la vega, thank you for joining us. i'm going to ask you to do some reality checks here. you are in a lot of spaces. home motivation. moving more into cars and wearables are connecting to your network more and more. which of these areas, say between home automation and wearables is not there as much? which is more real? >> back to your point is everything is connected in this show. cars are connected. there are autonomous vehicles. everybody wants to connect the home, the car and everything in between. and i love the leadership position that we have had where our vision for doing that is that the smartphone becomes your remote control for your life. with your smartphone and the capables, you can control your car. you can control your home. and everything in between and the coffee pot if you want to. we think ther

one trial will be run by glaxosmithkline, the other by merck. the vaccines will be tested on people who are most at risk of ebola. health care workers, other caregivers and possibly burial workers as well. >>> world leaders are paying tribute today to the late king of saudi arabia. the desert nation paid its last respects to king abdullah. the funeral service was today. he was one of the most powerful men on earth controlling one-fifth of the world's oil assets. in switzerland, secretary of state john kerry said people of saudi arabia and the world will miss the king's wisdom. >> king abdullah had a long history of being a brave partner with us and with the world in his work not just in counterterrorism but in his work on interfaith understanding. >> his half brother salman says he will continue his policies. >>> a prisoner has written a book detailing his captivity. the author is mahmoud salahi. his handwritten manuscript was heavily redacted before publication. it describes the torture and humiliation that he says he has been a regular part of

. >> i live in new jersey and sellgene is the biggest employer next the merck and they are pulling outare drugs similar to the ones you mentioned. do you ever look at what the other guy is doing and say, we shouldn't go there because the other guy has a better franchise than us? >> yeah. we are always looking at the competitive landscape. in multiple sclerosis, for example, we saw a great opportunity for an oral compound in a disease area which has been largely marked by injectables, interferons and other injectables. the need for unique safe tolerable therapieses is significant in m.s. and inflammatory bowel disease. we look at all of the compound ss that our competitors are developing and try to make sure we are bringing something forward that's unique and has a real opportunity, advantage to impact patients. >> you did that so i presume you don't need a partner, you can keep the rights and you don't -- you're really not -- if someone wanted to buy you, you could stand alone, right? >> look yeah. our intention is to build a sustainable organizeationorganization. we have rp1063 which